Morgan Stanley analyst Michael Ulz reiterated an Overweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE